SCHEMBL4173192

SCHEMBL4173192

C=CCOC(=O)c1cn(CC)c2ccc(CCCOCCO)cc2c1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.49
LMNA P02545 4/20 0.48
KMT2A Q03164 3/20 0.46
HPGD P15428 5/20 0.43
ALDH1A1 P00352 7/20 0.41
HSD17B10 Q99714 5/20 0.41
KDM4E B2RXH2 4/20 0.41
TSHR P16473 1/20 0.41
RAB9A P51151 1/20 0.41
MEN1 O00255 2/20 0.41
MAPT P10636 1/20 0.41
THRB P10828 1/20 0.41
POLB P06746 1/20 0.38
MAPK1 P28482 2/20 0.38
USP2 O75604 1/20 0.38
HTT P42858 1/20 0.37
PDE4A P27815 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5437230 0.87 SMN1; SMN2 (0.52) SMN1; SMN2LMNAKMT2AHPGDALDH1A1
SCHEMBL4169635 0.85 SMN1; SMN2 (0.36) SMN1; SMN2LMNAKMT2AHPGDALDH1A1
SCHEMBL3812462 0.85 KDM4E (0.57) LMNAKMT2AHPGDALDH1A1HSD17B10
SCHEMBL3816853 0.83 LMNA (0.62) SMN1; SMN2LMNAKMT2AHPGDALDH1A1
SCHEMBL14529470 0.81 KDM4E (0.57) LMNAKMT2AHPGDALDH1A1HSD17B10
SCHEMBL4172191 0.80 LMNA (0.67) SMN1; SMN2LMNAKMT2AHPGDALDH1A1
SCHEMBL5425671 0.80 KMT2A (0.50) SMN1; SMN2LMNAKMT2AHPGDALDH1A1
SCHEMBL27713849 0.78 LMNA (0.69) SMN1; SMN2LMNAKMT2AHPGDALDH1A1
SCHEMBL14529468 0.78 KDM4E (0.56) LMNAKMT2AHPGDALDH1A1HSD17B10
SCHEMBL4385083 0.78 LMNA (0.45) LMNAKMT2AHPGDALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090062218-A1 MACROLONE COMPOUNDS GLAXO GROUP LIMITED (GB) 2009-03-05 US disclosed
US-20090062218-A1 MACROLONE COMPOUNDS GLAXO GROUP LIMITED (GB) 2009-03-05 US disclosed
US-20090062218-A1 MACROLONE COMPOUNDS GLAXO GROUP LIMITED (GB) 2009-03-05 US disclosed
EP-1824871-A1 MACROLONE COMPOUNDS GLAXO GROUP LIMITED (GB) 2007-08-29 EP disclosed
WO-2006050940-A1 MACROLONE COMPOUNDS GLAXO GROUP LIMITED (GB) 2006-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062218-A1 MACROLONE COMPOUNDS CYP51A1, MRPL21, MYD88 SMN1; SMN2 2560/4885LMNA 1055/4885KMT2A 3931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.